Moreover, Prasse et al. have suggested a cut-off point of serum CCL18 concentration as a routine measurement in the management of IPF patients, although with caution, as CCL18 is increased in other fibrotic lung diseases with prognoses differing from IPF [34]. The gene discussed is CCL18; the disease is idiopathic pulmonary fibrosis.